학술논문

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Document Type
Article
Author
Dayan, Gustavo HRouphael, NadineWalsh, Stephen RChen, AiyingGrunenberg, NicoleAllen, MaryAntony, JohannesAsante, Kwaku PokuBhate, Amit SureshBeresnev, TatianaBonaparte, Matthew ICelle, MédéricCeregido, Maria AngelesCorey, LawrenceDobrianskyi, DmytroFu, BoGrillet, Marie-HeleneKeshtkar-Jahromi, MaryamJuraska, MichalKee, Jia JinKibuuka, HannahKoutsoukos, MargueriteMasotti, RogerMichael, Nelson LNeuzil, Kathleen MReynales, HumbertoRobb, Merlin LVillagómez Martínez, Sandra MSawe, FredrickSchuerman, LodeTong, TinaTreanor, JohnWartel, T AnhDiazgranados, Carlos AChicz, Roman MGurunathan, SanjaySavarino, StephenSridhar, SaranyaAbalos, KarinaAccini, JoseAloysia, NaveenaAmuasi, John HumphreyAnsah, Nana AkosuaBenkeser, DavidBerge, AudeBeyko, HannaBilotkach, OleksandraBreuer, ThomasBonfanti, Alberto CadenaBukusi, ElisabethCanter, RichardCarrillo, Jaime AugustoChansinghakul, DanayaCoux, FlorenceDas, ChandanDas, Santa KumarDevlin, LouisEspinoza, LuisFay, MichaelFollmann, DeanFrago, CarinaGaringa, AgnesGilbert, Peter BGonzalez, ClaudiaGranados, Maria AngelicaGuillery, LeaHuang, YingHudzina, KathyJain, ManishKanodia, PiushKhandelwal, NitinMutuluuza, Cissy KityoKiweewa, FrancisKiwanuka, NoahKosolsak, ChalitKukian, DarshnaKushwaha, Jitendra SinghLaot, ThelmaLopez-Medina, EduardoMacareno Arroyo, HugoMandaliya, KishorchandraMamod, StephanieMangarule, SomnathMartínez, JavierMcClelland, ScottMenard, LisaMendoza, SandraMohapatra, SatyajitMoreau, CatherineMugo, NellyNduba, VidelisNoriega, FernandoNtege, Patricia NahiryaOkech, BrendaOtero, MariaOuma, Samuel GurrionOyieko, JanetParedes, MercedesPardo, ErwinPostol, SvitlanaPekala, DavidPeng, PennyPy, Marie-LaureRivas, EnriqueRivero, RafaelRodriguez, EdithSaleh, MansoorSánchez, PedroSater, NessryneShah, JinenShrestha, RajeevSiika, AbrahamSingh, ChandramaniSingh, Veer BahadurTamrakar, DipeshTavares Da-Silva, FernandaOtieno Tina, LucasVelasquez, HectorWabwire, DeoWajja, AnneZaworski, ElodieZhang, Nianxian
Source
The Lancet Respiratory Medicine; 20230101, Issue: Preprints
Subject
Language
ISSN
22132600; 22132619
Abstract
COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed to describe the clinical efficacy and safety of a bivalent SARS-CoV-2 recombinant protein vaccine as a two-injection primary series during a period of circulation of the omicron (B.1.1.529) variant.